Mumbai –January 2026, Advent Chembio has announced N-Desmethyl Terbinafine as its Molecule of the Month forJanuary 2026, highlighting a critical pharmaceutical impurity widely used in analytical, regulatory, and quality-control applications related to antifungal APIs.
N-Desmethyl Terbinafine is a well-known process-related impurity and metabolite of Terbinafine, a widely prescribed antifungal drug used in the treatment of dermatophytic infections. Due to its close structural similarity to the parent API, the impurity plays a vital role in impurity profiling, analytical method development, stability testing, and ICH-compliant impurity control strategies.
From a scientific perspective, N-Desmethyl Terbinafine is extensively used as a reference impurity during HPLC and UPLC method development and validation. It is also relevant in forced degradation and stability studies, where its behavior helps establish the stability-indicating nature of analytical methods. Additionally, its role as a known metabolite makes it significant in toxicological and pharmacokinetic evaluations.
Advent Chembio has successfully developed and characterized N-Desmethyl Terbinafine with ≥95% purity, supported by comprehensive analytical data including HPLC purity, ¹H NMR, IR, and mass spectrometry. Each batch is supplied with a Certificate of Analysis (CoA), and potency data is provided where applicable. The material is currently available in ready stock, enabling prompt global delivery.
This announcement is part of Advent Chembio’s ongoing Molecule of the Month initiative, which focuses on spotlighting scientifically relevant pharmaceutical impurities and API working standards that support quality, compliance, and innovation in drug development.